Luna C. Schmacke

Luna C. Schmacke

Auto-generated profile, based on publicly available information

Luna C. Schmacke

Institute of Pharmaceutical Chemistry, Department of Pharmacy, Philipps University Marburg, Marbacher Weg 6-10, 35037 Marburg, Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2024 in Archiv der Pharmazie
Verified
Journal Article
Open access
SHSimon Huber
Simon Huber
NBNiklas J. Braun
Niklas J. Braun
LSLuna C. Schmacke
Luna C. Schmacke
RMRobin Murra
Robin Murra
DBDaniela Bender
Daniela Bender
TSTorsten Steinmetzer
Torsten Steinmetzer
Three new series of macrocyclic active site‐directed inhibitors of the Zika virus (ZIKV) NS2B–NS3 protease were synthesized. First, attempts were made to replace the basic P3 lysine residue of our previously described inhibitors with uncharged and more hydrophobic residues. This provided numerous compounds with inhibition constants between 30 and 50 nM. A stronger reduction of the inhibitory potency was observed when the P2 lysine was replaced by neutral residues, all of these inhibitors possess Ki values >1 µM. However, it is possible to replace the P2 lysine with the less basic 3‐aminomethylphenylalanine, which provides a similarly potent inhibitor of the ZIKV protease (Ki = 2.69 nM). Crystal structure investigations showed that the P2 benzylamine structure forms comparable interactions with the protease as lysine. Twelve additional structures of these inhibitors in complex with the protease were determined, which explain many, but not all, SAR data obtained in this study. All individual modifications in the P2 or P3 position resulted in inhibitors with low antiviral efficacy in cell culture. Therefore, a third inhibitor series with combined modifications was synthesized; all of them contain a more hydrophobic d‐cyclohexylalanine in the linker segment. At a concentration of 40 µM, two of these compounds possess similar antiviral potency as ribavirin at 100 µM. Due to their reliable crystallization in complex with the ZIKV protease, these cyclic compounds are very well suited for a rational structure‐based development of improved inhibitors.

21 November 2022 in ChemMedChem
Verified
Journal Article
Open access
NBNiklas J. Braun
Niklas J. Braun
SHSimon Huber
Simon Huber
LSLuna C. Schmacke
Luna C. Schmacke
AHAndreas Heine
Andreas Heine
TSTorsten Steinmetzer
Torsten Steinmetzer
The Zika virus (ZIKV) remains a potential threat to the public health due to the lack of both an approved vaccination or a specific treatment. In this work, a series of peptidic inhibitors of the ZIKV protease with boroleucine as P1 residue was synthesized. The highest affinities with Ki values down to 8 nM were observed for compounds with basic residues in both P2 and P3 position and at the N‐terminus. The low potency of reference compounds containing leucine, leucine‐amide or isopentylamide as P1 residue suggested a covalent binding mode of the boroleucine‐derived inhibitors. This was finally proven by crystal structure determination of the most potent inhibitor from this series in complex with the ZIKV protease.

20 November 2024 in Viruses
Verified
Journal Article
Open access
PDF file
MSMarie Schwerdtner
Marie Schwerdtner
LSLuna C. Schmacke
Luna C. Schmacke
JNJulia Nave
Julia Nave
HLHannah Limburg
Hannah Limburg
TSTorsten Steinmetzer
Torsten Steinmetzer
EBEva Böttcher-Friebertshäuser
Eva Böttcher-Friebertshäuser
The zoonotic transmission of influenza A viruses (IAVs) and coronaviruses (CoVs) may result in severe disease. Cleavage of the surface glycoproteins hemagglutinin (HA) and spike protein (S), respectively, is essential for viral infectivity. The transmembrane serine protease 2 (TMPRSS2) is crucial for cleaving IAV HAs containing monobasic cleavage sites and severe acute respiratory syndrome (SARS)-CoV-2 S in human airway cells. Here, we analysed and compared the TMPRSS2-dependency of SARS-CoV, Middle East respiratory syndrome (MERS)-CoV, the 1918 pandemic H1N1 IAV and IAV H12, H13 and H17 subtypes in human airway cells. We used the peptide-conjugated morpholino oligomer (PPMO) T-ex5 to knockdown the expression of active TMPRSS2 and determine the impact on virus activation and replication in Calu-3 cells. The activation of H1N1/1918 and H13 relied on TMPRSS2, whereas recombinant IAVs carrying H12 or H17 were not affected by TMPRSS2 knockdown. MERS-CoV replication was strongly suppressed in T-ex5 treated cells, while SARS-CoV was less dependent on TMPRSS2. Our data underline the importance of TMPRSS2 for certain (potentially) pandemic respiratory viruses, including H1N1/1918 and MERS-CoV, in human airways, further suggesting a promising drug target. However, our findings also highlight that IAVs and CoVs differ in TMPRSS2 dependency and that other proteases are involved in virus activation.

22 July 2025 in Journal of Virology
Verified
Journal Article
Open access
CBCaroline Bost
Caroline Bost
FTFilipe Tomaz
Filipe Tomaz
LSLuna C. Schmacke
Luna C. Schmacke
SRSven Reiche
Sven Reiche
NSNabil G. Seidah
Nabil G. Seidah
KFKerstin Fischer
Kerstin Fischer
Nairobi sheep disease virus (NSDV) is a tick-borne orthonairovirus, which is genetically related to Crimean-Congo hemorrhagic fever virus (CCHFV), and causes severe hemorrhagic gastroenteritis in infected sheep. CCHFV GP38, a cleavage product of the CCHFV glycoprotein precursor (GPC), has recently attracted attention: not only has GP38 been reported to elicit detectable anti-GP38 antibodies in CCHFV-infected patients, but anti-GP38 antibodies have also been shown to protect mice from lethal CCHFV challenge. While proteolytic cleavage of CCHFV GP38 has been described to involve the proprotein convertases furin and subtilisin/kexin-isozyme-1 (SKI-1), little is known about the processing of NSDV GPC, or the occurrence and immunogenicity of NSDV GP38 in infected sheep. Here, we provide the first evidence for the presence and immunogenicity of NSDV GP38 in infected sheep demonstrating seroconversion by the detection of anti-GP38 antibodies over the course of infection. To further characterize GPC processing in vitro , we investigated the impact of furin overexpression and the effect of a furin inhibitor on NSDV glycoprotein expression, cleavage, and viral infectivity. While virus infectivity remained unaffected, our results suggest that other proteases besides furin may play a role in the proteolytic processing of NSDV GPC at a cleavage site that remains to be explored. Taken together, our findings highlight the immunogenicity of NSDV GP38 in sheep and warrant further research into the similarities and differences in proteolytic cleavage between the glycoproteins of NSDV and other orthonairoviruses, such as CCHFV. IMPORTANCE: Nairobi sheep disease virus (NSDV) is a zoonotic orthonairovirus causing severe and often fatal hemorrhagic gastroenteritis in small ruminants. Its genetic relationship to human-pathogenic Crimean-Congo hemorrhagic fever virus (CCHFV) and striking similarities in the clinical picture between CCHFV-infected patients and NSDV-infected ruminants have led to the idea that NSDV could serve as a model organism to study CCHFV pathogenesis. However, knowledge on NSDV-host interactions has been limited. While CCHFV GP38 has recently attracted attention as vaccine candidate and possible virulence factor, the occurrence and role of putative GP38 in other orthonairoviruses has been unclear. This study provides first evidence for the presence and immunogenicity of NSDV GP38 in infected sheep. Furthermore, our data indicate that other proteases besides furin may be involved in the proteolytic cleavage of NSDV GPC. Future studies are needed to determine the proteases involved and to investigate the possible functional role of GP38 in NSDV pathogenesis.

2 April 2026 in Antibiotics
Verified
Journal Article
Open access
PDF file
LTLilla Tóth
Lilla Tóth
AMAndras Marosi
Andras Marosi
LSLuna C. Schmacke
Luna C. Schmacke
TSTorsten Steinmetzer
Torsten Steinmetzer
ARAnita Rácz
Anita Rácz
EGErzsébet Pásztiné Gere
Erzsébet Pásztiné Gere
Background/Objectives: Transmembrane serine proteases such as TMPRSS2 and matriptase have been identified as pivotal host factors in the influenza A infection due to their capacity to cleave the hemagglutinin and thereby facilitate viral activation. The inhibition of these enzymes has the potential to serve as an effective therapeutic strategy against numerous seasonal influenza strains. In our study, four 3-amidinophenylalanine-derived inhibitors were used to elucidate their antiviral efficacy, pharmacokinetic properties and affinities toward certain related trypsin-like serine proteases. Methods: Ki values for TMPRSS2, matriptase, thrombin and factor Xa were determined using enzyme kinetic measurements. Cytochrome P450 3A (CYP3A) inhibitory activity was investigated using human liver microsomes, and protein binding was evaluated with human serum albumin and α1-acid glycoprotein. In vitro antiviral efficacy and cytotoxicity were determined in MDCK-II cells. Results: All compounds were non-cytotoxic and exhibited a relatively high affinity toward matriptase and bovine thrombin in the 10–30 nM concentration range. Among the inhibitors, MI-441 displayed the lowest Ki value for TMPRSS2 (~60 nM). The weakest CYP3A inhibitory activity was observed for compounds MI-447 and MI-448. In addition, three of the four compounds (MI-441, MI-443 and MI-447) demonstrated significant antiviral activity. Conclusions: This study demonstrates that the investigated inhibitors exhibit a favorable safety profile, low binding to human serum albumin and pronounced antiviral activity against H1N1.